CN109414423A - 包含丙戊酸的延迟释放药物制剂和其用途 - Google Patents

包含丙戊酸的延迟释放药物制剂和其用途 Download PDF

Info

Publication number
CN109414423A
CN109414423A CN201780025746.XA CN201780025746A CN109414423A CN 109414423 A CN109414423 A CN 109414423A CN 201780025746 A CN201780025746 A CN 201780025746A CN 109414423 A CN109414423 A CN 109414423A
Authority
CN
China
Prior art keywords
acid
vpa
pharmaceutically acceptable
patient
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780025746.XA
Other languages
English (en)
Chinese (zh)
Inventor
尼尔斯·奥韦·古斯塔夫松
汉斯·罗格·马库斯·莫滕松
尼克拉斯·贝里
约纳斯·法耶尔松·萨廖
斯韦克·耶恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cereno Scientific AB
Original Assignee
Cereno Scientific AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cereno Scientific AB filed Critical Cereno Scientific AB
Priority to CN202111575415.8A priority Critical patent/CN114209667A/zh
Publication of CN109414423A publication Critical patent/CN109414423A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201780025746.XA 2016-04-08 2017-04-10 包含丙戊酸的延迟释放药物制剂和其用途 Pending CN109414423A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111575415.8A CN114209667A (zh) 2016-04-08 2017-04-10 包含丙戊酸的延迟释放药物制剂和其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201606197 2016-04-08
GB1606197.0 2016-04-08
PCT/GB2017/051002 WO2017175013A1 (en) 2016-04-08 2017-04-10 Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111575415.8A Division CN114209667A (zh) 2016-04-08 2017-04-10 包含丙戊酸的延迟释放药物制剂和其用途

Publications (1)

Publication Number Publication Date
CN109414423A true CN109414423A (zh) 2019-03-01

Family

ID=58709491

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780025746.XA Pending CN109414423A (zh) 2016-04-08 2017-04-10 包含丙戊酸的延迟释放药物制剂和其用途
CN202111575415.8A Pending CN114209667A (zh) 2016-04-08 2017-04-10 包含丙戊酸的延迟释放药物制剂和其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111575415.8A Pending CN114209667A (zh) 2016-04-08 2017-04-10 包含丙戊酸的延迟释放药物制剂和其用途

Country Status (15)

Country Link
US (2) US11395808B2 (https=)
EP (1) EP3439649B1 (https=)
JP (1) JP6985368B2 (https=)
KR (1) KR102438395B1 (https=)
CN (2) CN109414423A (https=)
AU (1) AU2017246697B2 (https=)
CA (1) CA3018043A1 (https=)
ES (1) ES2969021T3 (https=)
HU (1) HUE064701T2 (https=)
IL (1) IL262163B2 (https=)
MX (1) MX395521B (https=)
PL (1) PL3439649T3 (https=)
RU (1) RU2760304C2 (https=)
WO (1) WO2017175013A1 (https=)
ZA (1) ZA201806766B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113995742A (zh) * 2021-10-22 2022-02-01 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 包含丙戊酸的美白组合物及其用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
CA3018043A1 (en) 2016-04-08 2017-10-12 Cereno Scientific Ab Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
US20240285636A1 (en) * 2021-06-14 2024-08-29 Libbs Farmacêutica Ltda Pharmaceutical composition and use of the pharmaceutical composition
GB2613900B (en) * 2021-12-20 2024-01-17 Cereno Scient Ab Novel compounds and methods of use thereof
WO2026068561A1 (en) 2024-09-24 2026-04-02 Cereno Scientific Ab Valproic acid for use in treating pulmonary arterial hypertension

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276848A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
CN101947209B (zh) * 2010-07-21 2012-07-25 河南中帅医药科技发展有限公司 双丙戊酸钠小丸及其制备方法
CN103648492A (zh) * 2011-03-09 2014-03-19 赛伦诺科学有限公司 利用组蛋白脱乙酰酶抑制物改善受损的内源纤维蛋白溶解作用的化合物和方法
CN104248627A (zh) * 2013-06-25 2014-12-31 北大方正集团有限公司 丙戊酸半钠泡腾干混悬剂及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE68346T1 (de) 1987-07-22 1991-11-15 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeurezubereitung und verfahren zu ihrer herstellung.
CN1228043C (zh) * 1999-09-30 2005-11-23 爱德华·孟岱尔股份有限公司 用于高溶解度药物的缓释基质
AT408718B (de) * 1999-12-02 2002-02-25 Gerot Pharmazeutika Natriumvalproat-granulat mit verringerter hygroskopizität
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
ITMI20011733A1 (it) 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
JP2006507297A (ja) 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US20040224006A1 (en) 2003-04-21 2004-11-11 Samn Raffaniello Ancrod irradiated, impregnated or coated sutures and other first aid or wound management bandaging materials for minimizing scarring and/or preventing excessive scar formation
ITMI20040876A1 (it) 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
WO2006117165A2 (en) 2005-05-02 2006-11-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Means and methods for the treatment of head injuries and stroke
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
EP1937236A2 (en) 2005-09-07 2008-07-02 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
TWI393708B (zh) 2005-09-08 2013-04-21 Mei Pharma Inc 異羥肟酸脂化合物，其用途及其之合成方法
US20070082046A1 (en) * 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
DE602006003848D1 (de) * 2006-01-11 2009-01-08 Teva Pharma Formulierung zur verzögerten Freisetzung von Valproinsäure und deren Derivate
WO2007084775A2 (en) 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
US20090312311A1 (en) 2006-04-06 2009-12-17 Gary Michael Ksander Combination of organic compounds
US20080069878A1 (en) 2006-08-31 2008-03-20 Gopi Venkatesh Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs
GB2454118B (en) 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2009009737A1 (en) * 2007-07-12 2009-01-15 Neurosci, Inc. Sustained release formulation of active pharmaceuticals in a lipid based sustained release
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
JP6330118B2 (ja) 2011-09-13 2018-05-30 ファーマサイクリックス エルエルシー ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
CA3018043A1 (en) 2016-04-08 2017-10-12 Cereno Scientific Ab Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
WO2017175010A1 (en) 2016-04-08 2017-10-12 Cereno Scientific Ab Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276848A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
CN101947209B (zh) * 2010-07-21 2012-07-25 河南中帅医药科技发展有限公司 双丙戊酸钠小丸及其制备方法
CN103648492A (zh) * 2011-03-09 2014-03-19 赛伦诺科学有限公司 利用组蛋白脱乙酰酶抑制物改善受损的内源纤维蛋白溶解作用的化合物和方法
CN104248627A (zh) * 2013-06-25 2014-12-31 北大方正集团有限公司 丙戊酸半钠泡腾干混悬剂及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L. DIANE BRUCE等: "Properties of enteric coated sodium valproate pellets", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113995742A (zh) * 2021-10-22 2022-02-01 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 包含丙戊酸的美白组合物及其用途
CN113995742B (zh) * 2021-10-22 2023-12-29 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 包含丙戊酸的美白组合物及其用途

Also Published As

Publication number Publication date
AU2017246697A1 (en) 2018-10-04
AU2017246697B2 (en) 2022-06-02
JP6985368B2 (ja) 2021-12-22
IL262163B1 (en) 2023-03-01
IL262163A (en) 2018-11-29
BR112018070626A2 (pt) 2019-02-05
EP3439649C0 (en) 2023-11-15
NZ746269A (en) 2024-10-25
RU2018137399A (ru) 2020-05-12
MX395521B (es) 2025-03-25
RU2018137399A3 (https=) 2020-06-18
US20190111011A1 (en) 2019-04-18
US20230120670A1 (en) 2023-04-20
RU2760304C2 (ru) 2021-11-23
EP3439649A1 (en) 2019-02-13
CN114209667A (zh) 2022-03-22
HUE064701T2 (hu) 2024-04-28
KR20180127480A (ko) 2018-11-28
IL262163B2 (en) 2023-07-01
EP3439649B1 (en) 2023-11-15
JP2019510834A (ja) 2019-04-18
ES2969021T3 (es) 2024-05-16
PL3439649T3 (pl) 2024-03-18
US12023311B2 (en) 2024-07-02
US11395808B2 (en) 2022-07-26
ZA201806766B (en) 2024-03-27
WO2017175013A1 (en) 2017-10-12
CA3018043A1 (en) 2017-10-12
MX2018012224A (es) 2019-05-16
KR102438395B1 (ko) 2022-08-30

Similar Documents

Publication Publication Date Title
JP6480420B2 (ja) コルヒチンの徐放性製剤およびその使用方法
RU2616516C2 (ru) Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль
CN109414423A (zh) 包含丙戊酸的延迟释放药物制剂和其用途
US20140099366A1 (en) Composition Containing Two Anti-Dementia Drugs
RU2467750C2 (ru) Ниацинсодержащие фармацевтическая композиция (варианты) и таблеточный препарат (варианты), способ снижения гиперемии и способ приготовления ниацинсодержащей таблетки
US20110038931A1 (en) Composite preparation
JP2020535158A (ja) ニラパリブ処方物
JP2018162255A (ja) デフェラシロクスの経口製剤
PL200957B1 (pl) Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej
JP7592001B2 (ja) エフロルニチンとスリンダクの固定用量複合製剤
US20090069275A1 (en) Low flush niacin formulation
JP6191883B2 (ja) 制御放出製剤
KR20100059912A (ko) 알리스키렌 및 발사르탄의 제약 조합물
RU2672573C2 (ru) Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин
CZ298851B6 (cs) Tableta pro rízené podávání úcinných látek
US20120141586A1 (en) Thrombin receptor antagonist and clopidogrel fixed dose tablet
KR20200116867A (ko) 에스오메프라졸 또는 이의 약학적으로 허용 가능한 염을 포함하고 이중방출 프로파일을 갖는 약학적 조성물
KR20240141090A (ko) 용출률이 개선된 닌테다닙을 포함하는 약제학적 조성물
RS66829B1 (sr) Kompozicija furazidina sa produženim oslobađanjem
JP2018516274A (ja) コルヒチンサリチル酸塩およびこの利用
US20150224056A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
JP6887043B2 (ja) コルヒチンの徐放性製剤およびその使用方法
TWI606847B (zh) 口腔內崩解錠
US20140322313A1 (en) Pharmaceutical compositions of ibuprofen and an h2 receptor antagonist
RU2773029C2 (ru) Галеновые композиции органических соединений

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190301